Bloom Burton Reaffirms “Accumulate” Rating for Knight Therapeutics (GUD)
Other equities research analysts have also recently issued reports about the stock. TD Securities boosted their price target on shares of Knight Therapeutics from C$9.50 to C$10.00 in a research report on Friday, August 10th. Raymond James set a C$10.25 price target on shares of Knight Therapeutics and gave the stock an outperform rating in a research report on Thursday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of C$10.15.
GUD traded up C$0.11 during trading on Friday, hitting C$8.30. The company had a trading volume of 198,100 shares, compared to its average volume of 134,380. Knight Therapeutics has a one year low of C$7.38 and a one year high of C$8.81.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
See Also: Bond
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.